240 publications
Palbociclib (Ibrance®) for the treatment of metastatic breast cancer
Zorginstituut Nederland carried out an assessment of the medicine palbociclib (Ibrance®), whereby they came to the following ...
Netupitant - palonosetron (Akynzo®) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy
Zorginstituut Nederland has assessed the medicine netupitant/palonosetron (Akynzeo®), whereby they came to the following ...
Zinnige Zorg room for improvement report - Appropriate use of pharmaceutical products for patients with castration-refractory prostate cancer
Within the framework of the Zinnige Zorg Programme, Zorginstituut Nederland systematically assesses the Dutch minimal and ...
Zinnige Zorg room for improvement report - Appropriate post-treatment surveillance of women treated for breast cancer
Within the framework of the Zinnige Zorg Programme, Zorginstituut Nederland systematically assesses the Dutch minimal and ...
Fingolimod (Gilenya®)
Zorginstituut Nederland has advised on amending the conditional inclusion of the medicine fingolimod (Gilenya®) in the Medicines ...
Future scenarios about drug development and drug pricing
This report is the result of a consultative and deliberative process — initiated by the Belgian Healthcare Knowledge Centre (KCE) ...
Guideline for economic evaluations in healthcare
This new Guideline unifies all previously available Dutch guidelines, links up with international developments, provides un ...
Tranylcypromine (Tracydal®) in patients with a severe multi-resistant depressive disorder
Zorginstituut Nederland carried out a budget impact analysis for the medicine tranylcypromine (Tracydal®). They reached the ...
Tolperison (Tolpermyo®)
Zorginstituut Nederland has drawn up a pharmacotherapeutic report for the medicine tolperison (Tolpermyo®), whereby it reached ...
Brivaracetam (Briviact®)
Zorginstituut Nederland has approved a pharmacotherapeutic report for the medicine brivaracetam (Briviact®), whereby they reached ...